
    
      All subjects will receive 3 doses of study vaccine, including 2 doses of active vaccine and 1
      dose of placebo. All subjects will attend formal study center visits for safety and
      immunogenicity assessments on Days 0, 10, 42, 182, 192, 224, 549, 559, 591, and 729. A
      telephone contact to assess safety will be made at Day 364 and Day 909.
    
  